Related Experiment Video

Updated: Jun 6, 2026

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

[Gene IL6 G(-174)C and gene IL10 G(-1082)A polymorphisms are associated with unfavourable outcomes in patients with

K A Blagodatskikh, M A Evdokimova, Iu V Agapkina

    Molekuliarnaia Biologiia
    |November 25, 2010
    PubMed

    Insights

    Genetic variations in Interleukin-10 (IL10) influence coronary artery disease (CAD) outcomes. The Interleukin-6 (IL6) gene polymorphism, when combined with IL10, also impacts CAD prognosis in the Russian population.

    Area of Science:

    • Genetics
    • Cardiology
    • Immunology

    Context:

    • Coronary artery disease (CAD) is a significant global health concern.
    • Genetic factors play a role in CAD susceptibility and progression.
    • Inflammation is a key process in the development of atherosclerosis and CAD.

    Purpose:

    • To investigate the association between IL6 G(-174)C and IL10 G(-1082)A gene polymorphisms and coronary artery disease (CAD) in the Russian population.
    • To determine the impact of these genetic variations on patient outcomes and survival.
    • To explore potential combined effects of IL6 and IL10 polymorphisms on CAD prognosis.

    Summary:

    • A study of 1145 Russian patients with CAD examined IL6 and IL10 gene polymorphisms.
    • The IL10 G(-1082)A polymorphism showed an association with unfavorable outcomes, with A alleles linked to shorter survival times.
    • While IL6 G(-174)C alone did not show significant differences, its combination with IL10 polymorphisms indicated that specific genotypes (GG for IL6 and GA/AA for IL10) were associated with poorer outcomes.

    Impact:

    • The findings suggest that IL6 and IL10 gene polymorphisms, involved in the inflammatory system, play a role in the accelerated development of complications in patients with coronary syndrome.
    • This research contributes to understanding the genetic underpinnings of CAD and may inform personalized risk assessment strategies.
    • Identifying genetic markers could lead to targeted interventions for high-risk individuals.

    More Related Videos

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry05:53

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

    Published on: June 21, 2018

    Related Concept Videos

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    Single Nucleotide Polymorphisms-SNPs01:05

    Single Nucleotide Polymorphisms-SNPs

    A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
    Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

    Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

    The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
    Acute Coronary Syndrome III: Diagnostic Studies01:30

    Acute Coronary Syndrome III: Diagnostic Studies

    Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...